CN Bio FDA collaboration expanded

CN-Bio Innovations

Date 11 May 2021

The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications.

CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the U.S. Food and Drug Administration (FDA) has extended their research collaboration, for a further three years. The scope of the research carried out with the FDA’s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio’s lung-on-a-chip using the PhysioMimix™ MPS platform, to appraise the system’s use for the evaluation of inhaled drug products and assessing additional applications for CN Bio’s liver model.

CN Bio FDA collaboration expanded

Cambridge Future Tech Expands its Board with the Appointment of Michael Beer and Jem Davies as Non-Executive Directors

Xampla welcomes former P&G chemist to team as scale-up accelerates

Cambridge Future Tech Marks a Milestone with Its Inaugural London Pitch Event

Join an ambitious, supportive community of world-class scientists, engineers and entrepreneurs

You might also be interested in these articles

Cambridge Future Tech Expands its Board with the Appointment of Michael Beer and Jem Davies as Non-Executive Directors

Xampla welcomes former P&G chemist to team as scale-up accelerates

Cambridge Future Tech Marks a Milestone with Its Inaugural London Pitch Event

Join an ambitious, supportive community of world-class scientists, engineers and entrepreneurs